Insulin Glargine
drugOn this page
Also known as AbasaglarAbasaglar (previously abasria)Abasaglar kwikpenBasaglarBasalinBasalogGalactusGlarginGlargineGlariconHOE 71GTHOE 901HOE-71GTHOE-901HOE901Ins lantusIns lantus opticlikIns lantus optisetIns lantus solostar
Summary
Insulin Glargine (CHEMBL1201497) is an approved protein (ATC A10AE04); indicated across 14 conditions including diabetes mellitus and type 1 diabetes mellitus.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: A10AE04
- Indications: 14 conditions
- Clinical trials: 483
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201497 |
| Name | Insulin Glargine |
| Type | Protein |
| Max phase | 4 |
| ATC | A10AE04 |
Also known as: Abasaglar, Abasaglar (previously abasria), Abasaglar kwikpen, Basaglar, Basalin, Basalog, Galactus, Glargin, Glargine, Glaricon, HOE 71GT, HOE 901
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
14 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| diabetes mellitus | 4 | MONDO:0005015 | EFO:0000400 |
| type 1 diabetes mellitus | 4 | MONDO:0005147 | MONDO:0005147 |
| type 2 diabetes mellitus | 4 | MONDO:0005148 | MONDO:0005148 |
| leukemia | 3 | MONDO:0005059 | EFO:0000565 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| prediabetes syndrome | 3 | MONDO:0006920 | EFO:1001121 |
| hyperglycemia | 3 | MONDO:0002909 | HP:0003074 |
| hypertensive disorder | 3 | MONDO:0005044 | EFO:0000537 |
| atherosclerosis | 3 | MONDO:0005311 | EFO:0003914 |
| coronary artery disorder | 3 | MONDO:0005010 | EFO:0001645 |
| cystic fibrosis | 3 | MONDO:0009061 | MONDO:0009061 |
| acute myocardial infarction | 3 | MONDO:0004781 | EFO:0008583 |
| diabetic retinopathy | 0 | MONDO:0005266 | EFO:0003770 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 483.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 191 |
| PHASE3 | 178 |
| PHASE1 | 61 |
| Not specified | 28 |
| PHASE2 | 21 |
| EARLY_PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03087032 | PHASE4 | RECRUITING | Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) |
| NCT05553093 | PHASE4 | RECRUITING | Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes |
| NCT07117240 | PHASE4 | ENROLLING_BY_INVITATION | Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes |
| NCT07173712 | PHASE4 | NOT_YET_RECRUITING | Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes |
| NCT00174681 | PHASE4 | COMPLETED | Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes |
| NCT00174824 | PHASE4 | COMPLETED | Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients |
| NCT00184626 | PHASE4 | COMPLETED | Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes. |
| NCT00191178 | PHASE4 | COMPLETED | Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes |
| NCT00191282 | PHASE4 | COMPLETED | Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes |
| NCT00191464 | PHASE4 | COMPLETED | Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes |
| NCT00206401 | PHASE4 | COMPLETED | Lantus in the Treatment of Type 1 Diabetes Children |
| NCT00258804 | PHASE4 | COMPLETED | Insulin Glargine During and After the Period of Fasting in Ramadan |
| NCT00268645 | PHASE4 | COMPLETED | Insulin Glargine in Type 2 Diabetes |
| NCT00272077 | PHASE4 | COMPLETED | Insulin Glargine in Type 2 Diabetes Mellitus |
| NCT00279201 | PHASE4 | COMPLETED | The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) |
| NCT00283049 | PHASE4 | TERMINATED | Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control |
| NCT00309465 | PHASE4 | COMPLETED | Perioperative Insulin Glargine Dosing Study |
| NCT00311818 | PHASE4 | COMPLETED | Insulin Glargine in Type 2 Diabetes Mellitus |
| NCT00313742 | PHASE4 | COMPLETED | The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins |
| NCT00313937 | PHASE4 | COMPLETED | SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1 |
| NCT00322075 | PHASE4 | COMPLETED | LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous |
| NCT00335465 | PHASE4 | COMPLETED | Lantus Effect on Myocardial Glucose Metabolism in T2 |
| NCT00338104 | PHASE4 | COMPLETED | Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin |
| NCT00340613 | PHASE4 | COMPLETED | Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes |
| NCT00347100 | PHASE4 | COMPLETED | Insulin Glargine in Type 2 Diabetic Patients |
| NCT00349986 | PHASE4 | TERMINATED | LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus |
| NCT00353834 | PHASE4 | COMPLETED | The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes |
| NCT00354939 | PHASE4 | COMPLETED | Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement |
| NCT00358124 | PHASE4 | COMPLETED | Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy |
| NCT00360698 | PHASE4 | COMPLETED | Insulin Glulisine in Type 2 Diabetic Patients |
| NCT00360984 | PHASE4 | COMPLETED | Prevention of Severe Hypoglycemia in Type 1 Diabetes |
| NCT00367445 | PHASE4 | COMPLETED | A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus |
| NCT00377858 | PHASE4 | COMPLETED | Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX) |
| NCT00384085 | PHASE4 | COMPLETED | Insulin Glargine All to Target Trial |
| NCT00390728 | PHASE4 | COMPLETED | Insulin Glargine in Type I Diabetes Mellitus> Main Study AT.LANTUS: A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: HALT(Hypoglycaemia Avoidance With Lantus Trial) |
| NCT00399724 | PHASE4 | COMPLETED | A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus |
| NCT00405418 | PHASE4 | COMPLETED | Lantus Versus Levemir Treat-To-Target |
| NCT00418522 | PHASE4 | COMPLETED | This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus |
| NCT00469092 | PHASE4 | COMPLETED | Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes |
| NCT00483769 | PHASE4 | COMPLETED | One Year Glargine Treatment in CFRD Children and Adolescents |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).